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SUMMARY
BK polyomavirus (BKV) causes polyomavirus-asso-
ciated nephropathy and hemorrhagic cystitis in im-
munosuppressed patients. These are diseases for
which we currently have limited treatment options,
but potential therapies could include pre-transplant
vaccination with a multivalent BKV vaccine or thera-
peutics which inhibit capsid assembly or block
attachment and entry into target cells. A useful tool
in such efforts would be a high-resolution structure
of the infectious BKV virion and how this interacts
with its full repertoire of cellular receptors. We pre-
sent the 3.4-A˚ cryoelectron microscopy structure of
native, infectious BKV in complex with the receptor
fragment of GT1b ganglioside. We also present
structural evidence that BKV can utilize glycosami-
noglycans as attachment receptors. This work high-
lights features that underpin capsid stability and pro-
vides a platform for rational design and development
of urgently needed pharmacological interventions for
BKV-associated diseases.
INTRODUCTION
BK polyomavirus (BKV) is an opportunistic pathogen that causes
severe diseases in the immunosuppressed (Bennett et al., 2012).
Initial infection may occur through a respiratory or oral route, and
is either asymptomatic or causes a mild respiratory illness
(Goudsmit et al., 1982). A persistent infection is then established
in the kidney and urinary tract, and 80%–90% of the general
population are thought to be seropositive for the most prevalent
BKV genotypes (Antonsson et al., 2010; Egli et al., 2009;
Knowles et al., 2003; Stolt et al., 2003). In patients undergoing
immunosuppression following kidney or bonemarrow transplan-
tation, lytic replication can occur, causing polyomavirus-associ-
ated nephropathy (PVAN) and hemorrhagic cystitis (Moens et al.,
2017; Bennett et al., 2012; Ambalathingal et al., 2017). Up to 10%
of kidney transplant patients experience PVAN, with as many as
90% of these eventually losing their graft (Ramos et al., 2009).
The prevalence of BKV-associated disease is rising as the num-
ber of transplants increases (Bennett et al., 2012), and there is
alsomounting evidence that BKV, similar toMerkel cell polyoma-
virus, may be carcinogenic in humans (M€uller et al., 2017; Liu
et al., 2017; Papadimitriou et al., 2016; Luo et al., 2017; Frasca`
et al., 2015; Tillou and Doerfler, 2014; Feng et al., 2008). No
effective antivirals specifically targeting BKV are available (Ben-
nett et al., 2012; Ambalathingal et al., 2017), and so there is
increasing interest in the development of targeted therapeutics.
High-resolution structural information for the infectious BKV
virion and its interaction with cellular receptors would be a useful
resource in designing and evaluating such therapies.
Our current understanding of polyomavirus structure comes
largely from pioneering work by Caspar (Griffith et al., 1992; Ray-
ment et al., 1982) and Harrison (Stehle et al., 1996; Stehle and
Harrison, 1996; Liddington et al., 1991) on SV40 (which infects
Rhesusmonkeys), andmurine polyomavirus (PyV). Crystal struc-
tures revealed that polyomavirus capsids consist of 360 copies
of the major capsid protein VP1, which form 72 ‘‘pentons,’’
each consisting of a ring of five b barrel-containing VP1 mono-
mers (Nilsson et al., 2005). Together, these form a T = 7d lattice,
with a C-terminal arm from each VP1 making interactions with
neighboring pentons to stabilize the capsid shell. Essentially,
polyomaviruses position pentameric capsomers in what would
be the pentavalent and hexavalent positions of a true quasi-
equivalent lattice (Harrison, 2017; Caspar and Klug, 1962). The
asymmetric unit of these capsids therefore comprises six
quasi-equivalent VP1 chains, five of which form the pentons in
a hexavalent position, with the remaining VP1 chain from five
asymmetric units occupying a pentavalent position. A single
copy of the minor capsid protein VP2, or its N-terminal truncated
variant VP3, is incorporated within each penton (Chen et al.,
1998; Hurdiss et al., 2016).
Subsequently, there has been a shift toward using isolated
VP1 pentons for both structural and functional studies. Binding
experiments using such pentons, which cannot assemble into vi-
rus-like particles (VLPs), indicated that binding of free pentons to
cells requires the presence of sialylated glycans on the host cell
membrane (Maginnis et al., 2013; Neu et al., 2013a). Crystallo-
graphic structures of putative receptor ligands soaked into pen-
ton crystals have revealed the molecular mechanisms of recep-
tor recognition (Neu et al., 2010, 2012, 2013a, 2013b; Stehle and
Harrison, 1997). However, the major BKV receptors GD1b and
GT1b (Low et al., 2006) cannot be soaked into crystals, presum-
ably as a result of steric restrictions (Neu et al., 2013a). Further-
more, crystallization of isolated pentons requires the removal of
the N and C termini of VP1. Therefore, such structures do not
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allow us to understand how receptors are engaged by the native
virion, and penton structures may not capture the full range of
surface features which could be targeted by therapeutics.
Indeed, recent reports suggest BKV VLPs, but not pentons,
can use glycosaminoglycans (GAGs) to attach to target cells
(Geoghegan et al., 2017), suggesting that GAGs bind in regions
where different capsomers interact, which are missing from cap-
somer structures. Cryoelectron microscopy (cryo-EM) is poten-
tially well suited to determining the structures of intact virion:
receptor complexes, but no EM structure to date has sufficient
resolution to elucidate the interactions stabilizing the polyomavi-
rus capsid, or to identify bound ligands (current structures range
from 8 to 25 A˚ [Hurdiss et al., 2016; Li et al., 2015; Nilsson et al.,
2005; Shen et al., 2011; Griffith et al., 1992]).
Here, we use high-resolution cryo-EM to determine the struc-
ture of BKV at 3.8 A˚ resolution. This resolution allows us to high-
light differences between this human pathogen and those that
infect simian and murine hosts, which include differences in
how both the C-terminal arms and disulfide bonding stabilize
the capsid. The importance of disulfide bonds is confirmed by
a lower-resolution structure of BKV in reducing conditions in
which the density we ascribe to disulfide bonds disappears.
We also use a simple method analogous to crystallographic
soaking, to determine the structures of BKV bound to receptors:
the oligosaccharide moiety of ganglioside GT1b (at 3.4 A˚ resolu-
tion) and the model GAG heparin (at 3.6 A˚ resolution). Neither
receptor causes a conformational change in the capsid, presum-
ably functioning cooperatively to increase the avidity of attach-
ment to the host cell surface.
RESULTS
The High-Resolution Structure of BKV:Receptor
Complexes
BKV is difficult to concentrate to the levels required for optimal
cryo-EM data collection, so to increase the particle concentra-
tion and distribution of BKV for cryo-EM studies, multiple ali-
Figure 1. The Structures of BKV and
BKV:GT1b
(A) Isosurface representation of the 3.8 A˚ structure
of BKV viewed down the icosahedral 2-fold and
colored according to the radial coloring scheme
shown.
(B) Isosurface representation of the 3.4 A˚ structure
of BKV, in complex with GT1b (magenta). Repre-
sentative EM density containing the refined atomic
model is shown below each respective structure to
highlight the quality of the maps.
quots of purified virions were applied to
lacey carbon grids overlaid with a layer
of continuous carbon (Figure S1A). Owing
to the low concentration of our virus
samples and low affinity of polyomavirus:
receptor interactions (1–5 mM) (Neu
et al., 2008; Stehle and Harrison, 1996),
to study the BKV:GT1b structure we im-
plemented an on-grid soaking protocol,
where a 20 mM solution of the oligosaccharide portion of
GT1b was applied to the carbon-immobilized virions for 30 s
prior to blotting and plunge freezing (Figure S1B). Collectively,
these approaches allowed us to determine the structure of native
BKV at 3.8 A˚ resolution (Figures 1A and S1A), and in complex
with the oligosaccharide moiety of GT1b at 3.4 A˚ resolution (Fig-
ures 1B and S1B). The BKV and BKV:GT1b structures are essen-
tially identical, other than the presence of extra, high-resolution
density on the capsid surface corresponding to the oligosaccha-
ride portion of GT1b (see below).
As expected, the BKV capsid has a T = 7d quasi-symmetry,
and is built from 72 pentons of the major capsid protein VP1
(Figure 2A). Each of the six distinct conformations of VP1 pre-
sent within the asymmetric unit of the capsid shares a common
core fold (Figures 2B/2C), which is the b sandwich, ‘‘jelly roll’’
fold, characteristic of many viral capsid proteins. The C-terminal
arms, which invade adjacent capsomers to build the capsid, are
well-resolved, and at a slightly lower resolution than the VP1
core (on average 0.2 A˚ poorer; Figure S2). The resolution of
our map was sufficient to identify part of the shared C terminus
of VP2 and VP3, corresponding to residues 288–301 in the VP2
sequence (Figures 2D and 2E). While all pentons contain sym-
metry-averaged density for VP2/3 (Hurdiss et al., 2016), only
the pentavalent capsomeres contained density into which an
atomic model could be built. This density is located at the
base of the pentons as described previously for an isolated
VP1 penton from PyV (Chen et al., 1998), and describes a small
hydrophobic helix that is highly conserved in the VP2/3 se-
quences of polyomaviruses. The polypeptide sequence for
this modeled region differs by four residues between BKV and
PyV, one of which localizes to the hydrophobic helix (Chen
et al., 1998). Unlike PyV, there is much less interpretable density
toward the N terminus of this region for BKV, perhaps reflecting
increased mobility in this solution structure of the intact virion.
Beneath the VP2 density (in both BKV and BKV:GT1b struc-
tures), we see the same shells of density reported at lower res-
olution (Hurdiss et al., 2016), but these disappear with map
840 Structure 26, 839–847, June 5, 2018
sharpening, suggesting no high-resolution symmetric structure
is present for the packaged DNA.
Structural Comparison of BKV to the Non-human
Polyomavirus SV40
BKV and SV40 share 81.7% sequence identity in their major
capsid protein, VP1, so, as expected, the core fold of VP1 is
very similar in our BKV structure to that previously seen in
SV40. However, we were able to visualize differences in the
C-terminal arms of three of the six distinct conformers of VP1.
The biggest change is in chain 6 (gray in Figures 3A and 3B). In
SV40, the electron density is only interpretable to residue Gln355,
where the polypeptide backbone points away from the virion
(i.e., into bulk solution). In BKV, the polypeptide chain adopts a
different conformation from Tyr349 onward, and in the EMdensity
map this region is well resolved, allowing us to build an additional
four residues (up to Lys359). This segment is resolved in an
extended conformation that makes a series of interactions with
an arched structure formed by the C terminus of chain 3 (green
in Figure 3C). This is a significant difference with respect to the
conformation seen for SV40, as the conformation reported
here is consistent with the formation of up to ten potential addi-
tional H-bonding interactions.
Differences between BKV and SV40 are also observed at the
icosahedral 2-fold axes, which are formed at the interface be-
tween two adjacent chain 1s, in the region of residues 296–315
(Figure 3D). In BKV, the EM density is well resolved at the
2-fold axis, allowing us to build a conformation of the chain 1
polypeptide that forms an intimate hydrophobic interface around
which the 2-fold axis of the particle is constructed (Figure 3E).
This different conformation also results in a possible intramolec-
ular interaction in BKV between Arg214 (Lys in SV40) in the VP1
core and Asn310 in the C-terminal arm (Figures 3F and 3G).
Location of Disulfide Bonds and Ca2+ Binding within the
BKV Capsid
Polyomavirus capsids are stabilized by Ca2+ binding (Nilsson
et al., 2005), and two putative locations for Ca2+ binding have
been previously identified by the presence of gadolinium ions
in heavy metal soaking experiments for crystallographic struc-
ture determination of SV40 (Liddington et al., 1991). In our solu-
tion structures of BKV, we see a single density consistent with a
Ca2+ ion coordinated by glutamate side chains and the back-
bone carbonyl of a serine residue (Figure 4A). This location is
consistent with the proposed site 1 in SV40. However, no equiv-
alent density for anymetal ion binding at site 2 is present in any of
our structures.
Disulfide bond formation is also critical for capsid stability (Nils-
son et al., 2005), and their reduction/isomerization in the endo-
plasmic reticulum of an infected host cell appears to be an essen-
tial step in virion uncoating (Schelhaas et al., 2007; Jiang et al.,
2009). It has been shown previously that intermolecular disulfide
bonds between Cys104 residues serve to stabilize the SV40
capsid, and it has been suggested, but not shown, that Cys9
Figure 2. Atomic Model for the BKV Capsid and Interaction with the Minor Capsid Proteins
(A) The T = 7d icosahedral model of the BKV capsid viewed down an icosahedral 2-fold axis with each quasi-equivalent VP1 chain colored according to the color
key shown.
(B) A single asymmetric unit of the capsid showing the conformation of each of the C termini.
(C) Overlay of all the VP1 monomers in the asymmetric unit with the most variable regions (N terminus, C terminus, and CD loop) colored according to chain
number.
(D) Internal view of a 5-fold penton showing the model and EM density (2.2 swithin 1.6 A˚ of fitted coordinates) for the C-terminal region of VP2/VP3 binding at the
base of the two adjacent VP1 monomers (gray).
(E) Enlarged view of VP2/VP3 as shown in (D).
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may also be involved in disulfide bonding. The presence of Cys
residues at position 104 is conserved between BKV and SV40,
but the conformations of the CD loops that contain Cys104 are
different. In SV40, the CD loops of chains 2, 3, and 6 were
observed in close proximity at an interface between pentavalent
and hexavalent pentons, but that SV40 structure was not able
to resolve which pair of chains participated in a disulfide bond
(Stehle et al., 1996). In BKV, the conformation of the CD loops
is different, and strongly suggests that a disulfide bond is formed
between the CD loops of chains 3 (green) and 6 (gray). The CD
loop of chain 2 (yellow) is orientated away from this interaction
(Figure 4B). In contrast to SV40, in BKV the N terminus of a chain
2 from an adjacent capsomere points toward the chain 2 CD loop.
In our sharpened map, we are not able to resolve density for the
first 13 residues of chain 2, suggesting this portion of the capsid is
less well ordered. However, in the unsharpened map, which re-
tains lower-resolution information, a bridge of density joins the
N terminus to the CD loop before turning and continuing toward
the encapsidated genome (Figure 4C). This density is entirely
consistent with a Cys104-Cys9 disulfide bond. A similar bridge of
density is observed beneath the icosahedral 2-fold axes where
the N terminus of chain 4 bridges to the CD loop of chain 1 (Fig-
ure 4E). As there is no high-resolution density for these interac-
tions, we sought to confirm the presence of Cys104-Cys9 disulfide
bonds by determining the structure of BKV under reducing condi-
tions (Figures S3A–S3C). The resulting structure is less ordered
and has poorer resolution (6.5 A˚) than the non-reduced structure
(3.8 A˚), likely reflecting the decreased rigidity of the virion. For
direct comparison, the reduced and non-reduced structures
were low-pass filtered to 7 A˚. Crucially, the density for the
Cys104-Cys9 disulfides are completely absent in the reduced
structure (Figures 4D and 4F).
The Interaction of BKV with GT1b Oligosaccharide
GT1b is a branched oligosaccharide, described previously as
having ‘‘left’’ and ‘‘right’’ arms (Neu et al., 2013a) (Figure 5F).
The disialic acid motif located on the right arm, of GT1b is well
resolved in the 3.4 A˚ map (Figures 5A and 5B). The binding
mode is similar to that seen previously in a structure of GD3,
an oligosaccharide that lacks a left arm, bound to a BKV VP1
penton. The left arm of GT1b is poorly resolved in our structure,
indicating that it is not ordered at high resolution. To examine the
possible location of the GT1b left arm, we emphasized lower-
resolution features in the map by applying a 5 A˚ low-pass filter
to the 3.4 A˚ map. This revealed bridges of density between
Asp59 and Lys83 of VP1 and theGT1b density (Figure 5C), consis-
tent with previousmutagenesis data of these residues (D59Y and
K83A), which resulted in significantly reduced BKV spread in cell
Figure 3. The C Terminus of BKV
(A) Atomic model of the 5-fold coordinated pentamer colored as described in Figure 2.
(B) Enlarged view of the C terminus of chain 6 with the equivalent region from SV40 colored black.
(C) Enlarged view of the extended conformation shown in (B) showing potential hydrogen bonds between the C terminus of chains 6 and 3 of BKV.
(D) Atomic model of two adjacent hexavalent pentamers which make up the icosahedral 2-fold.
(E) The symmetry-related C termini of chain 1 indicated by a box in (D), showing the hydrophobic interaction between residues 296–304 with EM density for the
sharpened map (3 s).
(F) A single VP1 monomer of chain 1 for BKV showing the equivalent C terminus of SV40 (black).
(G) Enlarged view of the possible intra-chain interaction denoted by a box in (F) showing EM density for the sharpened map low-pass filtered to 4 A˚ (2 s).
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culture (Neu et al., 2013a). We also performed molecular dy-
namics simulations on a penton in complex with five GT1b mol-
ecules. For direct comparison with the EM density map the 3D
density distribution of the GT1b heavy atoms was calculated
from the accumulated 5.5 ms simulations (Figure 5D). A snapshot
from this simulation reveals an orientationwhere Asp59 and Lys83
could interact with the left arm of GT1b (Figure 5E). Additional in-
teractions identified during the simulation are shown in Figure S4,
and it is evident that the left arm contributes to binding affinity
through multiple transient interactions with the BKV surface.
To investigate recent reports of non-sialylated GAGs acting as
receptors for BKV infection, we again utilized on-grid binding
with the same heparin used in recently published inhibition as-
says (Figure S5A) (Geoghegan et al., 2017). The final sharpened
map had a resolution of 3.6 A˚ (Figures S5B and S5C), and again
there are no obvious structural differences in the BKV capsid
comparedwith the BKV and BKV:GT1b structures. However, un-
like the sharpened BKV-GT1b map, no obvious density for hep-
arin was visible at high resolution. To identify potential low-reso-
lution modes of binding, difference maps were calculated
between the low-pass-filtered versions of themaps. The location
of the resulting GT1b difference density is in agreement with our
model of the branchedGT1bmolecule (Figure 5G), while density,
which we ascribe to heparin, is located as a smear between the
capsomers, and at the top of each capsomer pore (Figure 5H).
Figure 4. Location of Calcium Ions and Di-
sulfides within the BKV Virion
(A) The calcium binding site in the sharpened BKV
map with EM density for calcium shown at 6 swith
surrounding residues colored according to the
corresponding chain.
(B) Atomic model of the CD loops of chains 2, 3,
and 6 and the N terminus of an adjacent chain 2
from BKV with EM density shown at 1.5 s.
(C) Density from the unsharpened, non-reduced
BKV map low-pass filtered to 7 A˚ (0.5 s), showing
additional density extending from the N terminus of
chain 2 and connecting to the CD loop of an
adjacent chain 2.
(D) Analogous region to that shown in (C) from the
unsharpened reduced BKV map low-pass filtered
to 7 A˚ (0.5 s).
(E) Density from the unsharpened BKV map low-
pass filtered to 7 A˚ (1s), showing additional density
extending from the N terminus of chain 4 and
connecting to the CD loop of chain 1.
(F) Analogous region to that shown in (E) from the
unsharpened reduced BKV map low-pass filtered
to 7 A˚ (1 s).
The density between the capsomers lo-
cates the putative site of heparin binding
atop a patch of positive charge on the
virion surface (Figures S5D and S5E).
DISCUSSION
The structures of BKV presented here
provide a detailed view of a native, infec-
tious, human polyomavirus. The overall
architecture of the BKV capsid is essentially the same as previ-
ously described for SV40 and PyV. However, the quality and
completeness of the cryo-EM structures means that we are
able to describe the different conformations of the C termini of
VP1 in a particle in solution. The C termini play a fundamental
role in the assembly and stability of a polyomavirus capsid,
adopting six distinct conformations that allow a single VP1
sequence to adopt all of the positions in a T = 7d lattice. It is un-
clear whether the differences we observe arise from sequence
differences between SV40 and BKV or from the different solution
conditions of the experiments. It should be noted, however, that
the solution structures determined herein, are in more native-like
conditions than those used to determine the crystal structures
(Lattman, 1980; Stehle and Harrison, 1996). So, whether differ-
ences arise from experimental conditions or sequence variation,
they provide insights into the structure of a human pathogen in
near-native conditions. The intersubunit interactions described
here (Figures 3 and 4) have implications for the structure and sta-
bility of the virus. The conformation observed for the C terminus
of chain 6 (Figure 3B) suggests that it interacts with a loop of
the C-terminal arm of chain 3, generating up to 10 potential
H-bonding interactions (Figure 3C). Given that this interaction
occurs 60 times in an intact capsid, this represents a significant
source of additional stability for the BKV virion. In addition, amino
acid variations between some BKV serotypes map to this region
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of the C terminus of VP1, indicating a possible role in antigenicity
(Pastrana et al., 2013).
A different conformation is also evident in the C termini of
chain 1, which make the 2-fold axes of the BKV and SV40
capsids (Figures 3D–3G), forming a tighter andmore intimate hy-
drophobic interface. Interestingly, we see additional differences
beneath (i.e., at lower radius) this interface. The N terminus of
chain 4 and the CD loop of chain 1 appears to make a disulfide
bond (Cys9-Cys104), which would further stabilize the capsid in
this region. We are also able to refine the model of how pentava-
lent and hexavalent pentons are linked by disulfide bonds, as we
show that only disulfides between Cys104 residues in chains 3
and 6 are present in our structure. Furthermore, previous sug-
gestions that chain 6 might also disulfide bond to chain 2 would
not be possible in our structures. The chain 2 CD loop is in a
different conformation to that seen in SV40, which allows disul-
fide bonding to the N terminus of a second chain 2 molecule.
These observations allow us to account for the disulfide bonding
of all of the CD loops in the structure, and two of the N termini.
We therefore present a much more complete picture of disulfide
bonding in the capsid. The differences could reflect genuine dif-
ferences between BKV and SV40, or indicate that the SV40 in the
crystals from which the structure was solved was not in a fully
oxidized state.
Figure 5. Interaction of BKV with GT1b and
Heparin
(A) Isosurface representation of a single 5-fold
pentamer of the BKV-GT1b complex with the
capsid colored as in Figure 2 and GT1b (magenta).
(B) Enlarged view of the GT1b density (2 s) con-
taining the corresponding atomic model for the
disialic acid motif of the right arm, colored as in (D).
(C) The 5 A˚ low-pass-filtered BKV-GT1b EM den-
sity (blue mesh) containing the high-resolution in-
formation shown in (B).
(D)MD-derived atomdensitymap for the simulated
structure of GT1b overlaid with the 5 A˚ low-pass-
filtered EM density shown in (C).
(E) A snapshot of the MD simulated structure of
GT1b showing possible interactions of the left arm
with Asp59 and Lys83.
(F) SNFG-representation of GT1b oligosaccharide
showing the left and right arms of the molecule
(Varki et al., 2015).
(G) Isosurface representation of the unsharpened
and 8 A˚ low-pass-filtered BKV-GT1b map viewed
down the icosahedral 2-fold axis and colored ac-
cording to the radial coloring scheme shown (A˚).
The GT1b difference density (3.4 s) is shown
colored magenta.
(H) The unsharpened and 8 A˚ low-pass-filtered
isosurface representation of the BKV-heparin
structure, with the putative heparin difference
density (3.4 s) colored orange.
We also present structural data for two
different receptors bound to the surface
of the virus. In the 3–4 A˚ resolution range
of the structures presented, there is no
detectable conformational change in
VP1. In our BKV:GT1b structure, we are
able to resolve the disialic acid motif of the GT1b right arm to
high resolution, confirming a conserved mode of binding be-
tween the large B-series gangliosides and smaller variants stud-
ied previously. MD simulations show that the left arm of GT1b is
dynamic, explaining the lack of high-resolution density in our EM
map, and its previous intractability to crystallographic studies.
Low-resolution EM density and MD suggest a likely mechanism
of binding for the left arm of GT1b, in which multiple, weak inter-
actions occur with the VP1 surface. Such interactions provide
the structural correlate to previous mutagenic and functional
studies showing that the presence of a left arm enhances infec-
tivity (Neu et al., 2013a).
These results demonstrate the emerging role cryo-EM can
play in structural glycobiology, to complement existing nuclear
magnetic resonance and crystallographic approaches. The abil-
ity to produce polyomavirus-ligand structures at resolutions ap-
proaching that of X-ray crystallography also leads to the exciting
prospect that cryo-EM could be used to study small molecule in-
hibitors of BK infection or assembly, and indeed the structure of
BKV:GT1b presented here is an ideal platform for the in silico
design of such tool molecules. It is clear that neither GT1b nor
GAG binding induce detectable conformational change in the
VP1 component of the capsid, and presumably act simply as
attachment receptors to facilitate cell entry, where changes in
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redox state and pH can effect changes in capsid structure that
lead to uncoating (Jiang et al., 2009).
It is not possible to determine whether the density between
pentamers represents bound GAG molecules, but the lack of
resolution suggests that no single mode of binding exists. How-
ever, this site is positively charged, as are GAG binding sites
observed in other viruses (O’Donnell et al., 2009; Fry et al.,
1999). Density in the pore of each pentamer and at the 2-fold
axes would be subject to inappropriate symmetry averaging,
and so must be interpreted with great care. The possibility that
GAGs bind in the pore of the VP1 pentamer is intriguing however.
We see no evidence for an interaction betweenGAGs and VP2/3,
but the pore is directly above their location, and it is interesting to
note that BKV pseudoviruses that lack VP2 and VP3 are less effi-
cient at transducing a range of different cell types (Schowalter
andBuck, 2013), whichmight be partially explained by a reduced
affinity for GAGs. Indeed, the entire VP1 shell is remarkably
porous, potentially allowing other opportunities for the interac-
tions between minor capsid proteins and GAGs that have been
suggested for a related virus, human papillomavirus 16 (Guan
et al., 2017). Our observations provide structural clues about
GAG binding to BKV and may form a basis to determine the pre-
cise molecular mechanism of GAG interaction using shorter,
defined fragments of heparin, which may be more amenable to
high-resolution structural characterization. Interestingly GAG
analogs have reportedly been used to treat BKV-associated dis-
ease (Van der Aa et al., 2014; Winter et al., 2015; Isik et al., 2014;
Cervigni, 2015). The rationale for such treatments was based on
restoration of the barrier function of the bladder epithelium, but in
light of recent results (including those presented here), it is
possible that GAGsmay bind directly to BKV and perturb cellular
attachment or entry.
The rationale for the studies presented here is to inform the
design of future anti-BKV therapies. Such therapies could
include antibodies capable of neutralizing BKV, or BKV vaccina-
tion. HumanmAbswhich bind BKV virions have recently been re-
ported (Jelcic et al., 2015), and vaccination with BKV VLPs has
been shown to induce pan-specific immunity in mouse models
(Pastrana et al., 2013). Our structures of the native, reduced,
and receptor-bound virions provide a platform for understanding
such antibody responses to BKV, and features that underpin
vaccine stability. Going forward, co-structures with mAbs that
show BKV serotype-specific neutralization (Randhawa et al.,
2009), broad cross-neutralization, or non-neutralizing mAbs will
be key for guiding efforts to further develop therapies to protect
patients against BKV nephropathy (Buck, 2016).
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STAR+METHODS
KEY RESOURCES TABLE
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to, and will be fulfilled by, the lead contact, Neil A.
Ranson (n.a.ranson@leeds.ac.uk).
METHOD DETAILS
Cell Culture
Vero cells weremaintained in DMEMwith 10% fetal bovine serum (FBS) and 50 U/ml penicillin and streptomycin. Cells were grown at
37C with 5% CO2 in a humidified incubator.
Virus Growth
The genome of BKV Dunlop strain (a kind gift from Professor Michael Imperiale, University of Michigan) was prepared as reported
previously (Abend et al., 2007). Briefly, the genome was excised from the pGEM7 Dunlop plasmid by BamHI (New England Biolabs)
digestion and then recircularized using T4 Ligase (New England Biolabs). Vero cells were seeded into 4 x T75 flasks and transfected
with 4 mg DNA using NanoJuice (Novagen) according to the manufacturer’s instructions with a DNA to Core ratio of 1:2 and DNA to
Booster ratio of 1:3. Transfection complexes were removed 16 hr post transfection and replaced with fresh growth media. Ten days
post transfection the cells were harvested by scraping into the media and subjected to three rounds of freeze-thaw using liquid N2.
The crude virus stocks were used to infect 36 x T175 flasks of 50% confluent Vero cells at 37C; after 2 hr the virus was removed and
replaced with fresh growth media.
REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
PGEM7-Dunlop (BK virus Dunlop strain) Laboratory of Michael Imperiale,
University of Michigan
N/A
Chemicals, Peptides, and Recombinant Proteins
GT1b oligosaccharide CarboSynth Cat# OO16323
Heparin Sigma Cat# 4784
Deposited Data
Density map of BKV in complex with GT1b This paper Electron Microscopy Data Bank: EMD-3944
Density map of BKV in complex with heparin This paper Electron Microscopy Data Bank: EMD-3945
Density map of unliganded BKV This paper Electron Microscopy Data Bank: EMD-3946
Density map of reduced BKV This paper Electron Microscopy Data Bank: EMD-4212
Coordinates for the BKV-GT1b
asymmetric unit
This paper PDB: 6ESB
Experimental Models: Cell Lines
Vero cells ATCC CCL-81 RRID: CVCL_0059
Software and Algorithms
RELION 2.0 (Kimanius et al., 2016; Scheres, 2012) https://www2.mrc-lmb.cam.ac.uk/relion
MOTIONCOR2 (Zheng et al., 2017) http://msg.ucsf.edu/em/software/motioncor2.html
gCTF (Zhang, 2016) https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/
UCSF Chimera (Pettersen et al., 2004) https://www.cgl.ucsf.edu/chimera/ RRID:
SCR_004097
Coot (Emsley et al., 2010) https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/
coot/ RRID: SCR_014222
Phenix (Headd et al., 2012) https://www.phenix-online.org/ RRID: SCR_014224
PDBePISA (Krissinel and Henrick, 2007) http://www.ebi.ac.uk/pdbe/pisa/ RRID: SCR_015749
PyMOL (The PyMOL Molecular Graphics
System, Version 2.0, Schro¨dinger,
LLC)
https://pymol.org/ RRID: SCR_000305
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Virus Purification
BKV-infected Vero cells were harvested 21 days post infection and purified essentially as described previously (Shen et al., 2011).
Cells were harvested by scraping and pelleted at 4000 x g before being resuspended in 10 ml of buffer A (10 mM Tris, 50 mM NaCl,
0.01% Triton X-100) supplemented with an EDTA-free protease inhibitor cocktail (Roche). The lysate was freeze thawed 3 times with
3 min sonication in a water bath between each cycle. Deoxycholic acid was added to a final concentration of 0.25 % and incubated
for 30 minutes at 37C with shaking. The pH was then lowered to 6.0 with 0.5 M HEPES (pH 5.4) and 5 units of type V neuraminidase
(Sigma) was added. This was incubated at 37C for 1 hour with shaking and the pHwas raised back to 7.5 with 0.5MHEPES (pH 8.0).
The sample was then sonicated for 3 x 45 seconds in a water bath before pelleting the cellular debris at 4000 x g for 10 minutes. The
pellet was resuspended in 5ml of buffer A and this processwas repeated a further two times. The supernatants were combined over a
4 ml 20 % (w/v) sucrose cushion in buffer A before centrifugation at 85,000 x g for 3 hours at 4C in a SW32Ti rotor (Beckman). The
pellet was resuspended in 5ml of 1.34 g/ml CsCl and the isopycnic gradient was spun at 4C for 16 hours at 110,000 x g (no brake) in a
SW55Ti rotor (Beckman). The BKV band was collected using a 26-gauge needle and dialysed against 2 L of buffer A (without Triton
X-100) for 2 days at 4C. Dialysis buffer was exchanged twice with pre-chilled buffer A (without Triton X-100).
Electron Microscopy
Cryo-EMgrids were prepared by applying 3 ml of purified BKV (0.25mg/ml) to 400mesh lacey grids coated in a 3 nm carbon film (Agar
Scientific, UK). The sample was left to adsorb for 30 seconds before most of the sample was blotted awaymanually and this process
was repeated 4 times. For the reduced BKV structure, 5mMDTTwas added to the sample and incubated for 15minutes at RT prior to
preparing cryo-grids. On-grid binding of receptors was performed by applying 3 ml of a 20 mM solution of GT1b oligosaccharide
(CarboSynth) or heparin 10 mg/ml (Sigma – 4784) in Buffer A (without Triton X-100) to the pre-blotted, BKV-coated grid, and leaving
for 30 seconds before blotting and freezing using a Leica EM GP plunge freeze device (Leica Microsystems). The Leica EM chamber
temperature was set to 8C with 80 % relative humidity and liquid ethane was used for sample vitrification. Grids were glow dis-
charged for 30 seconds prior to application of the samples. All data sets were collected on an FEI Titan Krios (ABSL, University of
Leeds) transmission electron microscope at 300 kV, at a magnification of 75,000x and a final calibrated object sampling of
1.065 A˚/pixel. Exposures were recorded using the EPU automated acquisition software on a FEI Falcon II (unliganded BKV) or Falcon
III direct electron detector operating in linear mode. Detailed information on data collection is shown in Table S1.
Image Processing
Image processing was carried out using the RELION 2.0 pipeline (Kimanius et al., 2016; Scheres, 2012). Drift-corrected averages of
eachmovie were created using MOTIONCOR2 (Zheng et al., 2017) and the contrast transfer function of each determined using gCTF
(Zhang, 2016). Automated particle picking on lacey carbon grids resulted in a large number of boxes picked on the edges of holes in
the carbon film. To remove such ‘junk’ particles from the data sets, 2D classification in RELIONwas used with CTF amplitude correc-
tion only performed from the first peak of each CTF onwards. Particles were further classified using several rounds of both reference-
free 2D classification and 3D classification. After each round, the best classes/class was taken to the next step of classification.
Icosahedral symmetry was imposed during 3D auto-refinement and post-processing was employed to appropriately mask the
model, estimate and correct for the B-factor of the maps. The final resolutions were determined using the ‘gold standard’ Fourier
shell correlation criterion (FSC = 0.143) shown in Table S1. Local resolution was estimated in RELION which also generated maps
filtered by local resolution.
Model Building and Refinement
Apreliminarymodel for the BKV asymmetric unit was generated by rigid body fitting our previously published homologymodel (5FUA)
(Hurdiss et al., 2016) into the EM density map using UCSF Chimera (Pettersen et al., 2004). The model was then manually fitted in
Coot using the ‘real space refinement tool’ (Emsley et al., 2010). The resulting model was then symmetrized in Chimera to generate
the capsid and subject to refinement in Phenix (Headd et al., 2012). Iterative rounds of manual fitting in Coot and refinement in Phenix
were carried out to improve non-ideal rotamers, bond angles and Ramachandran outliers. For VP2, the murine polyomavirus coor-
dinates (1CN3) were aligned to a fivefold coordinated penton of BKV using UCSF Chimera. The VP2 model was then mutated, fitted
and refined in Coot before being subject to refinement in Phenix. For GT1b modelling, the coordinates for the oligosaccharide
component from the previously determined BKV penton – GD3 structure (Neu et al., 2013a) were used to model the disialic acid motif
from the ‘right’ arm of GT1b. Low-pass filtered maps were generated using RELION image handler and difference maps were gener-
ated in UCSF Chimera. Interactions between chains 6 and 3 were analyzed using PDBePISA (Krissinel and Henrick, 2007). Figures
were generated using UCSF Chimera and PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schro¨dinger, LLC).
Molecular Dynamics Simulations
The x-ray crystal structure 4MJ0 (Neu et al., 2013a), was used as a starting structure for MD. Missing protein loops were modelled
with YASARA (Krieger and Vriend, 2015). The GT1b oligosaccharide was built with AMBER tleap using Glycam06 building blocks
(Kirschner et al., 2008). The glycosidic torsions of the (2-8)-linkage were adjusted to the values found in the x-ray structure for
GD3 in site C. GT1b molecules were positioned into the four occupied binding sites by superimposing the terminal Neu5Ac (R)
with the terminal Neu5Acs present in the x-ray structure, respectively. An additional 5th GT1b molecule was manually positioned
into the remaining binding site resembling the same binding mode. During very long MD simulations, dissociation of ligands can
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occur, particularly when the bindingmode is not optimized at the beginning of the simulation as is the case for ‘docked ligands’. Since
the binding mode of the terminal Neu5Ac (R) is well established by several H-bonds, distance restraints (Asn-272:OD1-Neu5Ac:N5,
Ser-274:OG-Neu5Ac:O1A and Thr-276:OG1-Neu5Ac:O1B) were applied in order to guarantee that this residue stayed in the binding
site in a defined binding mode for the whole simulation. A periodic box was filled with a 0.1% NaCl solution, which resulted in a mo-
lecular system consisting of 126,430 atoms. The simulations were performed at 310 K with YASARA in ‘fast mode’ using AMBER14
(which includes Glycam06) as a force field. In total 1.1 ms trajectory data was sampled for the BKV/GT1b pentamer complex distrib-
uted over six independent simulations. This allowed analysis of GT1b dynamics in the binding site(s) of BKV over an accumulated
time of 5.5 ms. Snapshots were recorded every 50 ps, which gave a trajectory file consisting of 22,200 frames and produced about
20GByte binary trajectory data in XTC format. All analysis and generation of scientific plots was performedwith Conformational Anal-
ysis Tools (CAT) - www.md-simulations.de/CAT/. For calculation of the atom 3D density map all MD frames of the pentamer were
superimposed on the EM atomic model using a sequence alignment file. In order to average the density over the five sides the
five-fold symmetry was taken into account. Snapshots were visualized with VMD (Humphrey et al., 1996). Model coordinates are
available from the authors upon request.
QUANTIFICATION AND STATISTICAL ANALYSIS
Where appropriate, statistical details are given in the Method Details section. Table S1 contains quantitative parameters related to
data collection and image processing.
DATA AND SOFTWARE AVAILABILITY
The Cryo-EMmaps of BKV-GT1b, BKV-heparin, unliganded-BKV and reduced-BKV reconstructions were deposited in the Electron
Microscopy Data Bank under ID codes EMDB 3944, EMDB 3945, EMDB 3946 and EMDB 4212 respectively. The coordinates for the
BKV-GT1b asymmetric unit were deposited in the Protein Data Bank under the ID code PDB 6ESB.
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